Christian Poehlein - Concepedia

Author

Christian Poehlein

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

C H Poehlein, C. H. Poehlein, C. Poehlein, C.H. Poehlein, Christian H Poehlein, Christian H. Poehlein, Christian Heinrich Poehlein, Christian Poehlein, Haiyan Wu

151

Publications

6.9K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Radboud University Nijmegen Radboud University Medical Center Macquarie University Carolina Urologic Research Center

About

Christian Poehlein is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	24	1.4K
2	Health Sciences	10	10	367
3	Immunology	7	7	255
4	Diagnostic Sciences	5	5	177
5	Cell Biology	2	2	171

Christian Poehlein

Publications

6.5K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, New England Journal of Medicine	2017	3.3K
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, Journal of Clinical Oncology	2019	679
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin, NEJM Evidence UrologyGenitourinary CancerMedicineOlaparib ArmPolymerase Inhibitor Olaparib	2022	357
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer Nadeem A. Sheikh, Daniel P. Petrylak, Philip W. Kantoff, Cancer Immunology Immunotherapy	2012	260
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial Fred Saad, Noel W. Clarke, Mototsugu Oya, The Lancet Oncology UrologyOncologyGenitourinary CancerMedicineAbiraterone Versus Placebo	2023	256
Development of antitumor immune responses in reconstituted lymphopenic hosts. Hong‐Ming Hu, Christian Poehlein, Walter J. Urba, PubMed Adaptive Immune SystemNaïve T CellsImmunologyCd4 T Cell ResponsesImmune Cell Therapy	2002	136
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Journal of Clinical Oncology	2023	121
KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). Johann S. de Bono, Jeffrey C. Goh, Kristiina Ojamaa, Journal of Clinical Oncology UrologyAntitumor ActivityGenitourinary CancerMedicinePharmacology	2018	97
PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Fred Saad, Andrew J. Armstrong, Antoine Thiery-Vuillemin, Journal of Clinical Oncology Androgen ReceptorEndocrine OncologyUrologyOncologyGenitourinary Cancer	2022	80
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial Joaquı́n Mateo, Johann S. de Bono, Karim Fizazi, Journal of Clinical Oncology UrologyGenitourinary CancerMedicinePharmacologyProfound Trial	2023	79

Page 1